CryoCell International Inc (CCEL)vsJohnson & Johnson (JNJ)
CCEL
CryoCell International Inc
$3.51
-0.28%
HEALTHCARE · Cap: $29.56M
JNJ
Johnson & Johnson
$227.35
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 307957% more annual revenue ($96.36B vs $31.28M). JNJ leads profitability with a 21.8% profit margin vs -8.5%. CCEL appears more attractively valued with a PEG of 1.34. JNJ earns a higher WallStSmart Score of 59/100 (C).
CCEL
Hold39
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+56.6%
Fair Value
$7.69
Current Price
$3.51
$4.18 discount
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$227.35
$67.22 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 129 in profit
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Revenue declined 3.6%
Earnings declined 80.5%
Currently unprofitable
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEL
The strongest argument for CCEL centers on Return on Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : CCEL
The primary concerns for CCEL are Market Cap, Revenue Growth, EPS Growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CCEL profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
CCEL carries more volatility with a beta of 0.63 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 39/100), backed by strong 21.8% margins. CCEL offers better value entry with a 56.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?